Wall Street Analysts Give A Resounding 'Buy!' On AC Immune
AC Immune Ltd (NASDAQ: ACIU) has attracted Wall Street analysts' attention on Tuesday after more than three weeks since its 6.0 million IPO. Significantly, three brokerages have accorded a Buy or an Outperform rating on the stock.
AC Immune, which is a clinical stage biopharmaceutical firm, came out with its IPO in September. The company priced its IPO at $11.00 a share on September 22 and opened with 28 percent gain on the following day. The stock has traded between $13.01 and $19.97 since then.
Until now, the stock has already delivered more than 35 percent returns. Based on the three brokerage's least target price of $18, there is still upside potentials of about 18 percent. Similarly, the highest price objective of $25 reflected a possible upside of more than 60 percent.
The following are the ratings and price objectives assigned by brokerages:
- Credit Suisse initiated with an Outperform rating with $18 as the price objective.
- Jefferies started with a Buy rating with a price target of $25.
- Leerink Swan commenced with an Outperform rating and a target price of $22.
At last check, AC Immune was up 5.47 percent at $15.22.
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email firstname.lastname@example.org with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!
Latest Ratings for ACIU
|Oct 2016||Leerink Swann||Initiates Coverage On||Outperform|
|Oct 2016||Credit Suisse||Initiates Coverage On||Outperform|
|Oct 2016||Jefferies||Initiates Coverage On||Buy|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.